

## Pharmacy and Therapeutics (P&T) Committee Meeting Tuesday, August 22<sup>nd</sup> 2017, 6:00 p.m. to 8:00 p.m.

### Agenda

Topic:

Presenter:

<p><b>I. Welcome</b></p> <ul style="list-style-type: none"> <li>• Call to Order</li> <li>• Introduction(s)</li> </ul>	<p>Carl Antolick III, Chair</p>
<p><b>II. Conflict of Interest Statement</b></p>	<p>Dee Jones, EA</p>
<p><b>III. Minutes from May 23, 2017 Meeting*</b></p>	<p>Carl Antolick III, Chair</p>
<p><b>IV. Old Business</b></p> <ul style="list-style-type: none"> <li>• Formulary Development and Management at CVS Caremark®</li> </ul>	<p>Carl Antolick III, Chair</p>
<p><b>V. Formulary Updates*</b></p> <ul style="list-style-type: none"> <li>• 2018 Formulary Updates               <ul style="list-style-type: none"> <li>○ Removals</li> <li>○ Add Backs</li> </ul> </li> <li>• Hyperinflation Exclusions</li> <li>• Tier Changes               <ul style="list-style-type: none"> <li>○ Negative</li> <li>○ Positive</li> </ul> </li> <li>• New Drug Reviews               <ul style="list-style-type: none"> <li>○ Soliqua® 100-33</li> <li>○ Afstyla®</li> <li>○ Trulance®</li> <li>○ Tymlos®</li> <li>○ Rhofade®</li> <li>○ Rubraca®</li> <li>○ Rydapt®</li> <li>○ Vraylar®</li> </ul> </li> </ul>	<p>Carl Antolick III, Chair Carl Antolick III, Chair</p> <p>Carl Antolick III, Chair Carl Antolick III, Chair</p> <p>Jennifer Burch, PharmD, CDE David Konanc, MD John Anderson, MD John Anderson, MD Matthew Flynn, MD Michael Spiritos, MD Michael Spiritos, MD Randy Grigg, MD</p>
<p><b>VI. Utilization Management Policy Review*</b></p> <ul style="list-style-type: none"> <li>• New Policies               <ul style="list-style-type: none"> <li>○ Albenza®, Biltricide®, Emverm® Limit Policy</li> <li>○ Ciclopirox Topical Solution 8% Policy</li> <li>○ Elidel® Policy</li> <li>○ Protopic® Policy</li> </ul> </li> </ul>	<p>Carl Antolick III, Chair</p> <p>John Engemann, MD Matthew Flynn, MD Matthew Flynn, MD Matthew Flynn, MD</p>

- Soriatane® Policy
- Prudoxin®, Zonalon® Policy
- Sitavig® Policy
- Rosacea Policy
- Cuprimine®, Syprine® Policy
- Voltaren® Gel Policy
- Lidoderm® Policy
- Existing Policies
  - Daraprim® Policy
  - Difucid® Policy
  - Influenza Treatment Policy
  - Grastek® Policy
  - Oralair® Policy
  - Ragwitek® Policy
  - Solodyn®, Ximino® Policy
  - Restasis® Policy
  - Testosterone Oral Policy
  - Testosterone Policy
  - Solaraze® Policy

Matthew Flynn, MD  
 Matthew Flynn, MD  
 Matthew Flynn, MD  
 Matthew Flynn, MD  
 Joseph Shanahan, MD  
 Jennifer Burch, PharmD, CDE  
 Jennifer Burch, PharmD, CDE

John Engemann, MD  
 John Engemann, MD  
 John Engemann, MD  
 Joseph Shanahan, MD  
 Joseph Shanahan, MD  
 Joseph Shanahan, MD  
 Matthew Flynn, MD  
 John Anderson, MD  
 Jennifer Burch, PharmD, CDE  
 Jennifer Burch, PharmD, CDE  
 Jennifer Burch, PharmD, CDE  
 Carl Antolick III, Chair

**VII. Other Topics\***

- P&T Committee Charter

**VIII. Adjourn**

- Next Meeting: Tuesday, November 14, 2017
- Directions to the Longleaf Building

Carl Antolick III, Chair

\*Requires a vote by the P&T Committee